SCHEDULE: Adage Capital Management Discloses Forte Biosciences Stake

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has reported beneficial ownership of 6.84% of Forte Biosciences, Inc. common stock as of March 31, 2026.

Summary

• Adage Capital Management, L.P. (ACM), through its general partner Adage Capital Partners, L.P. (ACP), has filed a Schedule 13G, indicating beneficial ownership of Forte Biosciences, Inc. common stock.
• The filing also includes Robert Atchinson and Phillip Gross, who are managing members of entities that manage ACM and ACP, and are filing in their individual capacities.
• As of March 31, 2026, the reporting persons collectively beneficially own 950,000 shares of Forte Biosciences, Inc. common stock.
• This ownership represents approximately 6.84% of the company's outstanding common stock, based on 13,885,668 shares outstanding as of March 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance details of the underlying company, Forte Biosciences, Inc.

Positives

• Significant stake reported by a notable investment manager, Adage Capital Management, L.P.
• The reporting persons hold shared voting and dispositive power over 950,000 shares, indicating a coordinated investment strategy.
• The filing is made under Rule 13d-1(b), suggesting the reporting persons are institutional investors (investment advisers).

Negatives

• The filing does not contain specific financial performance data for Forte Biosciences, Inc., as it is a Schedule 13G disclosure of beneficial ownership.
• No information is provided regarding the reasons for acquiring this stake or future intentions beyond standard certifications.

Risks

• The filing does not explicitly mention any risks associated with Forte Biosciences, Inc. or the investment itself.
• Potential for future changes in beneficial ownership, which could impact the stock price.

Future Outlook

No specific forward-looking statements or guidance regarding Forte Biosciences, Inc. are provided in this Schedule 13G filing. The filing primarily concerns the reporting of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. Adage Capital Management's filing indicates a notable position in Forte Biosciences, Inc., which could signal confidence in the company's prospects or a strategic investment within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Adage Capital Management may influence investor sentiment and potentially impact share price due to the perceived institutional backing.
• Company Management: The reporting persons' stake may lead to increased engagement or scrutiny from Adage Capital Management regarding company strategy and performance.

Next Steps

• Monitor future filings from Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross for any changes in beneficial ownership.
• Review Forte Biosciences, Inc.'s subsequent financial reports and disclosures for operational updates and performance metrics.

Key Dates

Keywords

Forte Biosciences, Schedule 13G, Adage Capital Management, Beneficial Ownership, Investment Management, SEC Filing, Common Stock, Institutional Investor